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Abstract
Chronic obstructive pulmonary disease (COPD) is a major cause of disability, morbidity and
mortality in old age. Patients with advanced stage COPD are most likely to be admitted three to
four times per year with acute exacerbations of COPD (AECOPD) which are costly to manage.
The adverse events of AECOPD are associated with poor quality of life, severe physical disability,
loneliness, and depression and anxiety symptoms. Currently there is a lack of palliative care
provision for patients with advanced stage COPD compared with cancer patients despite having
poor prognosis, intolerable dyspnoea, lower levels of self efficacy, greater disability, poor quality of
life and higher levels of anxiety and depression. These symptoms affect patients' quality of life and
can be a source of concern for family and carers as most patients are likely to be housebound and
may be in need of continuous support and care. Evidence of palliative care provision for cancer
patients indicate that it improves quality of life and reduces health care costs. The reasons why
COPD patients do not receive palliative care are complex. This partly may relate to prognostic
accuracy of patients' survival which poses a challenge for healthcare professionals, including general
practitioners for patients with advanced stage COPD, as they are less likely to engage in end-of-life
care planning in contrast with terminal disease like cancer. Furthermore there is a lack of resources
which constraints for the wider availability of the palliative care programmes in the health care
system. Potential barriers may include unwillingness of patients to discuss advance care planning
and end-of-life care with their general practitioners, lack of time, increased workload, and fear of
uncertainty of the information to provide about the prognosis of the disease and also lack of
appropriate tools to guide general practitioners when to refer patients for palliative care. COPD
is a chronic incurable disease; those in an advanced stage of the disease pursuing intensive medical
treatment may also benefit from the simultaneous holistic care approach of palliative care services,
medical services and social services to improve quality of end of life care.
Introduction
Chronic obstructive pulmonary disease (COPD) is a
major cause of morbidity and mortality worldwide [1,2].
Studies in the US have reported death rate from COPD
doubled in the past two decades while significant decline
occurred in deaths rate from other chronic diseases, for
example, chronic heart disease and stroke [3,4]. The
trends of increasing annual death rate of COPD was also
marked by the first time the number of women dying
from COPD surpassed men [5] in contrast to demo-
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graphic changes in the general population. In the same
period healthcare utilization was exponentially growing
because patients with severe COPD were hospitalized
three to four times per year and utilization of intensive
care units for patients admitted with acute exacerbations
of COPD in developed countries [1,4-6]. In the US in
2005, the National Heart, Lung and Blood Institute
reported that the annual direct medical costs for COPD
were about $21.8 billion and indirect costs (restricted
days, lost workdays, and productivity) estimated at $17
billion respectively [7]. Au and co-workers [8] examined
retrospectively patients who died in the previous six-
months with advanced stage COPD in comparison with
lung cancer patients and their healthcare utilization. They
found that patients with COPD had 'twice the odds of
being admitted to an intensive care unit and received
fewer opiates and benzodiazepine compared with
patients with lung cancer'. The total direct medical costs
were $4,000 higher for COPD patients compared with
lung cancer patients because of the intensive care unit uti-
lization [8]. A recent population survey that investigated
the health status of COPD patients in five European coun-
tries and US have reported that a significant but minority
of European Union patients reported that their 'health sta-
tus was worse than death' because of significant impair-
ment in physical daily activities, severe dyspnoea, fatigue,
pain and psychological morbidity due to anxiety and
depressive symptoms [9].
In patents with severe COPD (defined forced expiratory
volume in one second, FEV1 < 1 litre), inpatient mortality
of 7.4% and 90 day mortality of 15% [10] and one year
mortality rate for elderly COPD patients range from 36%
[11] to 59% reported in patients admitted to intensive
care unit with acute exacerbations of COPD [12], and
compare unfavorably for cancer patients 'the 5-year rela-
tive survival rate for persons diagnosed with cancer is
62.7%, with variation by cancer site and stage at diagno-
sis' [13]. This article examines why patients with severe
advanced stage COPD do not receive appropriate pallia-
tive care simultaneously when receiving active treatment
despite presenting with low-self-esteem, poor health sta-
tus, low levels of physical activity, severe dyspnoea and
fatigue compared with cancer patients. These symptoms
are often associated with adverse events such as worsened
functional impairment, frequent hospitalization, and pre-
mature death.
Palliative care
A typical palliative care team may comprise of a physician,
mental health and palliative care nurses, auxiliary staff, a
pharmacist, bereavement counselor, psychologist, chap-
lain, social worker and volunteers etc. However because of
cost implication and different settings of the palliative
care services, the team may comprise some or all members
of the team. The purpose is to maximize care, relieve suf-
fering and improve quality of life for the patient and pro-
vide support for the family and carers with a team
approach. The level of care may vary depending on the
availability of staff and the set up of the palliative care pro-
gramme, for example, inpatient or nursing home. In addi-
tion it may rely on the outcome of assessment of the
palliative care team which may range from once daily or
more to two or three times per week by the appropriate
team members and with weekly review by the whole
team.
Currently palliative care services are not widely available
because of the high demand for care for patients with can-
cer and chronic progressive diseases which are costly to
manage. However, a recent survey data in the US hospitals
indicate an encouraging sign that the number of palliative
care programs increased from 2000 [n = 632 (15%) of
hospitals] to 2003 [n = 1027 (25%) of hospitals] [14].
Palliative care is not synonymous with terminal care and
it should be apparent that palliative care approach focuses
on symptom management, maintenance of a reasonable
quality of life, good communication (patients, family
members and physicians), increasing physical activities to
maintain independence and practical support of emo-
tional, spiritual and psychosocial support for patients and
caregivers [15]. Currently, palliative care is mostly availa-
ble for cancer patients who benefited from medical care to
control physical symptoms of pain, dyspnoea, and emo-
tional and spiritual support, at the end of life care [15].
However, this kind of provision is not widely available for
COPD patients. Gore and co-workers [16] investigated the
morbidity of end stage COPD in comparison to patients
with unresectable non-small lung cancer (NSCLC) [FEV1
< 0.75 litres versus 1.47 litres]. The COPD patients were
identified with poor quality of life, severe dyspnoea, and
psychological burden of clinically relevant anxiety or
depression (90% COPD versus 52% NSCLC). Despite
having worse prognosis, the COPD patients received no
palliative care compared with NSCLC patients. A recent
systematic review [17] that investigated the prevalence of
physical symptoms of five chronic progressive diseases
(advanced cancer, AIDS, heart disease, renal disease, and
COPD) identified common physical symptoms across the
five conditions which were pain, breathlessness, and
fatigue. In addition, a high prevalence of depression was
reported in COPD patients. This indicates that palliative
care is relevant for patients with all five chronic condi-
tions. However the holistic aspects of care provision and
management may require modification to satisfy individ-
ual patient's needs in order to improve quality of life and
to support carers and families.Health and Quality of Life Outcomes 2007, 5:17 http://www.hqlo.com/content/5/1/17
Page 3 of 6
(page number not for citation purposes)
The impact of depression can be profound in influencing
patient preferences of choice whether to receive a life sus-
taining treatment or not in patients with COPD [18]. In
an elegant qualitative study, Curtis and colleagues [19]
examined the differences in end-of-life care provision
from patient perspectives for patients with COPD, Cancer
and AIDS. The three groups differed in socio-demographic
characteristics, and COPD patients were older compared
with the Cancer and AIDS patients. However they have
reported similar concern of whether the family physicians
are skilled enough in providing end of life care (emo-
tional support, communication and accessibility and con-
tinuity of care). The COPD patients further reported the
desire for education to know more about the disease proc-
ess, treatment, and prognosis, what dying might be like
and advance care planning which may be a territory for
the palliative care team to address.
Why COPD patients do not receive palliative 
care?
General practitioners and healthcare professionals are
challenged by prognostic accuracy of patient survival in
patients with severe end-stage of COPD, and they are less
likely to engage in end-of-life care planning in contrast
with terminal diseases like cancer. This poses a challenge
about when to refer patients with advanced stage of
COPD for palliative care even though their physical, emo-
tional and psychosocial needs are as severe as or worse
than patients with lung cancer [16,20]. Furthermore there
is a lack of resources which constraints for the wider avail-
ability of the palliative care programmes in the health care
system.
Currently there is no research data to persuade health care
providers that palliative care provision for advanced stage
COPD patients has beneficial effects in terms of reducing
the healthcare utilization (for example, hospital readmis-
sion) or improving quality of life in this patient group.
However, a recent study [21] that investigated in male
patients the benefits of palliative care provision (predom-
inantly cancer including cardiovascular, pulmonary and
gastrointestinal etc.) compared with the usual care (opti-
mum medical treatment and hospital care provision).
Patients that received palliative care were less likely to be
admitted to intensive care unit during hospitalization,
incur lower inpatient costs per day, and receive better
medical care provision compared to the usual care
patients. Hence palliative care may help in reducing
health care costs and may avoid admission into the inten-
sive care unit for patients with COPD.
Acute exacerbations are common in patients with severe
COPD which require on average three-to-four times hos-
pital readmission per year and patients are most likely to
present with low self-esteem and suffer from a high level
of depressive and anxiety symptoms. Our research group
has reported recently that patients with severe acute exac-
erbation COPD identified at discharge with a co-morbid
depression have increased likely hood of (13% more) of
dying in the following year compared with non-depressed
patients [11]. This observation indicates the lack of holis-
tic palliative care provision for psychological, social sup-
port (patient and carers) and spiritual care at the end stage
of COPD.
Patients with severe COPD are most likely to be house-
bound, socially isolated, physically disabled, and lead
poor quality of life. They can be a source of concern for
family and carers, as some patients are chair-bound, and
may be in need of continuous support and care including
routine basic daily activities for example, bathing.
Benefits of palliative care for COPD patients
Palliative care for COPD patients will open an opportu-
nity for better communication with patient, family, and
physician in order to plan appropriate treatment strategies
including advance care planning, and patient preferences
with regard to choice of end of life withholding or with-
drawing medical treatment and hospice care. For the
details of topics and protocol guidelines to enhance
patient-doctor-communication and treatment options see
reviews [15,33].
The multidisciplinary nature of palliative care provision
may encourage COPD patients to play an active role in
self-management in order to optimize energy and func-
tion. In addition, the psychosocial support and the health
care professionals' care and attention may promote confi-
dence to over-come the disproportionate fear dyspnoea
on exertion brings may help to engage in routine daily
activities.
It will also provide unmet needs of the patients psycho-
logical, spiritual, and psychosocial needs in the advance
stage of the disease in order to improve patients' quality of
life. In addition, the spouse and/or carers are more likely
to suffer from anxiety and depressive symptoms providing
continuous care during the advance stage of the disease
and end of life care without having any periods of respite.
Therefore, it will open access to a specialist palliative care
team including home nursing services and referral to hos-
pice care.
What are the potential barriers?
Table 1 summarizes some of the potential barriers [22-24]
from the patients and the general practitioners perspec-
tives to provide satisfactory care for the patients at the end
stage of the disease. It requires a multi-modal approach to
tackle the barriers as follows.Health and Quality of Life Outcomes 2007, 5:17 http://www.hqlo.com/content/5/1/17
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The general practitioners may require further training on
communication skills in how to break sensitive informa-
tion such as the prognosis of the disease and advance care
planning [24]. It is also possible that general practitioners
may not have adequate time with increased workload to
discuss such kind of issues at great-depth. Hence, referring
those patients in advance stage of the disease to palliative
care team is a worthy endeavor.
Education of the patients and carers about the disease,
including the prognostic and advance care planning at the
early stage of the disease should be part of the pulmonary
rehabilitation program. This may increase patient's aware-
ness and confidence to ask relevant questions at the end-
stage of the disease and to have a meaningful conversation
with their physicians in order to devise appropriate treat-
ment strategies. In order to achieve these goals further
training is required to specialize on palliative care for the
pulmonary rehabilitation team and others (for example,
advanced practice nurses) that may be involved in patient
care to assist the general practitioners.
Assessment
Accurate assessment of the patients' psychological mor-
bidity, physical disability and impaired quality of life, is
the first step of towards planning good end of life care. A
recent study in our department identified physical disabil-
ity, poor quality of life and depression as predictors of
mortality following the events of acute exacerbations of
COPD in a preceding year [11]. The Manchester Respira-
tory Activities of Daily Living (MRADL) [25] is a self-
administered physical disability scale, and is specifically
validated as a postal questionnaire for patients with
COPD. The score ranges from 0 to 21, and a low score cor-
responds to severe physical disability in activities of daily
living. It takes less than five minutes to complete. The
MRADL [11] score < 10 showed predictive values for one
year mortality (sensitivity 75% and specificity 63%), i.e.
good at identifying mortality but less good at predicting
survival. The MRADL has a potential in identifying (select-
ing) severe COPD patients with physical disability that are
most likely to benefit from palliative care provision while
pursuing optimum medical treatment. The MRADL
requires testing in future research. Others have suggested
the BODE index (body mass index, airflow obstruction,
dyspnoea and exercise capacity) [26,27] might be a useful
tool as changes may relate to progression of disease and
predicts mortality in this patient group.
Treatment that may benefit COPD patients 
during palliative care provision
Long acting bronchodilators
It is important to be aware of the effects of drugs to keep
the airways open for a long period time in order to reduce
breathlessness and increase quality of sleep during the
night for the patient suffering from severe dyspnoea. Tio-
tropium (tiotropium bromide) is a safe long acting
inhaled bronchodilator drug with a long duration of pro-
viding sustained bronchodilation throughout the day,
and is relatively selective for muscarine M1 and M3 recep-
tors, dissociating more quickly from M2 receptors [28,29].
A recent meta-analysis showed that Tiotropium reduced
frequency of COPD exacerbations, relieved dyspnoea, and
improved quality of life in patients with COPD [30]. Once
daily dosing is convenient for patients but close monitor-
ing for adverse effects such as dry mouth and urinary tract
infections are essential.
Oxygen Therapy
In the advanced stage of the disease, COPD patients often
experience chronic hypoxia which may require oxygen
therapy as it helps to relieve dyspnoea and improve phys-
ical activities within a home environment. However, the
long-term benefits of oxygen therapy for COPD patients
remain inconclusive. A few studies have reported that
patients with COPD on long-term oxygen therapy (LTOT)
suffer from high level of anxiety and depressive symp-
toms, poor quality of life [31] and premature death com-
pared to non-LTOT patients with COPD [11].
Opiates
Morphine is commonly used for patients with intolerable
dyspnoea in palliative medicine. It helps the patient to
feel comfortable, reduce breathlessness and improves the
quality of sleeping pattern. Dosing depends on the symp-
tom burden and the patient history of exposure. A recent
review [32] supports the use of opioids to treat dyspnoea
(reducing the sensation of breathlessness) in patients with
Table 1: Potential barriers of discussing the prognosis end-stage of COPD [22-24]
Patients General practitioners
1) Unwillingness to discuss end of life care
2) Lack of communication (not sure which doctor will be taking care of 
me)
3) Ignoring not to discuss the issue
4) Lack of knowledge what type of care available
5) Loss of hope
1) Lack of confidence (ill-prepared to discuss the issue adequately)
2) Lack of time in busy surgery (increasing workload)
3) Uncertain about the information to provide about the prognosis in 
advance COPD
4) Lack of patient education about the end stage of COPD
5) Not in the priority list
6) Lack of resources and facilitiesHealth and Quality of Life Outcomes 2007, 5:17 http://www.hqlo.com/content/5/1/17
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advanced progressive diseases, including COPD. How-
ever, close monitoring of the patient condition for side
effects such as nausea, vomiting, dizziness and constipa-
tion is essential. Morison and Morison [33] advise when
ever possible to use the lowest effective dose of opioid
medication and titrate the bowel regimen accordingly.
Benzodiazepines
They can be considered in the treatment of severe dysp-
noea and anxiety symptoms including panic attack which
are common in patients with advance stage of COPD for
example, regular low-dose longer-acting benzodiazepines
such as diazepam 2–5 mg every 8 hours [34].
Psychosocial and spiritual needs
COPD patients with severe dyspnoea, tiredness and pain
may compromise their physical, psychological, social,
and spiritual aspects of their lives. Palliative care (a multi-
disciplinary care) holistic care approach addressing some
of the issues of may be a benefit for patients and families.
However, to-date the benefits of spiritual care has not
been explored in patients with COPD. It was reported that
spiritual and religious beliefs can play an important role
at the end of life care, for example, a question "are you at
peace?" offers a patient an opportunity to express his/her
spiritual concerns and to have a dialogue with the doctor
'in treatment decisions for patients and families, particu-
larly with regard to initiation of and continuation of life-
prolonging therapies' [35]. In this regard chaplains and
local church minister may play an active role to support
the patient and family in spiritual care.
Pulmonary rehabilitation
There is strong evidence to suggest that a group based pul-
monary rehabilitation program improves quality of life,
exercise capacity, and increases confidence to pursue
enjoyable hobbies for mild to moderate COPD patients.
However, patients with the advanced stage COPD with
physical and psychological symptoms (Table 2) especially
those housebound may derive-benefits, if the exercise pro-
gram is individually tailored, instructed and periodically
supervised by the therapist as a part of home exercise pro-
gram in that it may improve independence in physical
activities and self-management. It is worth exploring
whether the palliative care programme has any additional
benefits when simultaneously provided with pulmonary
rehabilitation programme.
Patients with severe dyspnoea may benefit from relaxa-
tion therapy and breathing training (breathing control)
exercises, appropriate positioning and advice on postural
correction can also be useful in reducing sensation of
breathlessness. Furthermore, providing a supportive lis-
tening environment, psychosocial counseling and reassur-
ing patients and respite care for caregivers may also be
beneficial. Devising coping strategies, adaptation of the
home environment, energy conservation techniques to
improve daily activities, for example, the inability to take
a shower while standing upright can be overcome by plac-
ing a chair in the bath/shower-room are worthy of consid-
eration. Malnutrition is common in advanced stage
COPD. Factors that contribute to this are multifactiorial
and may include the increased work of breathing because
of severity of lung impairment, decreased appetite and a
lack of balanced diet. The dietitian may provide an advice
to the patient and carers about diet and supplementary
diet intake. Patients with severe dyspnoea while eating
may benefit from dividing the daily intake into several
small meals.
In summary, palliative care is not available for patients
with advanced stage COPD despite their having a poor
prognosis with lower levels of self-efficacy, greater disabil-
ity, poor quality of life, and higher levels of anxiety and
depression worse than subjects with terminal non-small
cell lung cancer. COPD patients are twice as likely to be
admitted to an intensive care unit compared with lung
cancer patients. Indeed, COPD is a chronic incurable dis-
Table 2: Indicators of physical symptoms with advanced end stage of COPD
Social isolation
Depression
Anxiety
Poor quality of life
Intolerable dyspnoea
Frequent hospital admissions
Housebound or chair bound
Fatigue (excessive tiredness)
Loss of hobbies
Loss of weight
Low self-esteem
Long term oxygen therapy
FEV1 < 30%
FEV1 = Percentage of forced expiratory volume in one second.Publish with BioMed Central    and   every 
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ease, especially those in advanced stage of the disease pur-
suing intensive medical treatment may benefit from the
simultaneous provision of the holistic care approach of
palliative care services, medical services and social services
to improve quality of end-of-life care.
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